<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521546</url>
  </required_header>
  <id_info>
    <org_study_id>2011H0251</org_study_id>
    <nct_id>NCT01521546</nct_id>
  </id_info>
  <brief_title>Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy</brief_title>
  <acronym>E-SCAR DMD</acronym>
  <official_title>Early Treatment With Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Subha Raman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ballou Skies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Duchenne muscular dystrophy (DMD), the most common muscular dystrophy, leads to skeletal and
      cardiac muscle damage. Treatment of pulmonary complications has improved survival; however,
      heart muscle disease or cardiomyopathy has emerged as a leading cause of death, typically by
      the third decade. Although myocardial changes begin early, clinically significant heart
      disease is rarely detected in the first decade of life. Consequently, DMD cardiomyopathy
      frequently goes unrecognized (and untreated) until advanced (and irreversible).

      Current DMD cardiovascular care guidelines recommend beta-blockers and angiotensin converting
      enzyme inhibitors (ACEIs) when decreased ejection fraction (EF) is noted by echocardiography
      (echo); however, this strategy has not significantly improved outcomes. Our team has recently
      made a breakthrough in a mouse study, showing in a model that causes the same heart muscle
      disease in humans with DMD adding an old medicine traditionally used for high blood pressure
      and late-stage heart failure can actually prevent heart muscle damage. Because of this drug's
      proven safety in both children and adults, it is ready to be studied immediately in an RCT in
      patients with DMD to hopefully show, as we did in mice, that we can prevent the devastating
      consequences of heart muscle damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duchenne Muscular dystrophy (DMD) is a deadly X-linked disease affecting 1 in 3,500 males.
      DMD patients suffer significant disability due to skeletal myopathy and excess death due to
      cardiomyopathy. Current guidelines advocate initiating cardioprotective treatment with
      evident global cardiac dysfunction, yet this treatment paradigm has not improved survival
      much beyond the third decade of life. Potentially promising approaches like gene therapy will
      take considerable time to improve outcomes. Recently completed studies in a DMD mouse model
      at our institution indicate that existing drugs known as aldosterone antagonists, typically
      reserved for advanced heart failure patients, preserve skeletal and cardiac muscle function
      at 80% of normal. Clinical studies at many centers including ours have shown that
      high-resolution, noninvasive cardiac magnetic resonance (CMR) detects subclinical myocardial
      fibrosis and abnormal regional function prior to global functional abnormalities. Combining
      findings from these preclinical and clinical studies, we plan to execute a randomized,
      controlled clinical trial (RCT) of eplerenone plus background therapy vs. background therapy
      alone in patients with DMD. We expect that the aldosterone antagonist eplerenone compared to
      standard therapy significantly delays progressive cardiomyopathy and skeletal myopathy using
      highly reproducible imaging biomarkers selected for efficient sample size design, to
      ultimately reduce disability and death.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month Change in Myocardial Strain</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>a sensitive measurement of heart function using cardiac MRI, change was 12 months minus baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>eplerenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eplerenone</intervention_name>
    <description>25mg tablet, once daily by mouth for 12 months</description>
    <arm_group_label>eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one tablet by mouth daily for 12 months</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DMD patients age 7 years and older (and able to complete cardiac MRI without sedation)
             with preserved left ventricular (LV) systolic function and abnormal heart muscle by
             late post-gadolinium imaging (LGE)

        Exclusion Criteria:

          -  renal insufficiency (GFR &lt;40 mL/min/m2)

          -  non-MR compatible implants (e.g. neurostimulator, AICD)

          -  severe claustrophobia

          -  allergy to gadolinium contrast

          -  prior use of or known allergy to epleronone

          -  use of potassium-sparing diuretics

          -  serum potassium level of &gt;5.0 mmol/L
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subha V Raman, MD, MSEE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mattel Children's Hospital and David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1743</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S1474442214703187</url>
    <description>Journal article</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <results_first_submitted>April 21, 2015</results_first_submitted>
  <results_first_submitted_qc>May 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2015</results_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Subha Raman</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>cardiomyopathy</keyword>
  <keyword>aldosterone antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrollment was required prior to assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo
placebo: one tablet by mouth daily for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Eplerenone</title>
          <description>active study drug
eplerenone: 25mg tablet, once daily by mouth for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Males with Duchenne Muscular Dystrophy</population>
      <group_list>
        <group group_id="B1">
          <title>Eplerenone</title>
          <description>active study drug
eplerenone: 25mg tablet, once daily by mouth for 12 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo
placebo: one tablet by mouth daily for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" lower_limit="12.0" upper_limit="18.5"/>
                    <measurement group_id="B2" value="15.0" lower_limit="11.0" upper_limit="19.0"/>
                    <measurement group_id="B3" value="15.0" lower_limit="11.75" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>The study was approved for 42 participants and 42 participants were enrolled.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>12-month Change in Myocardial Strain</title>
        <description>a sensitive measurement of heart function using cardiac MRI, change was 12 months minus baseline.</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo: one tablet by mouth daily for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Eplerenone</title>
            <description>eplerenone one tablet by mouth daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>12-month Change in Myocardial Strain</title>
          <description>a sensitive measurement of heart function using cardiac MRI, change was 12 months minus baseline.</description>
          <units>percent change in heart dimension</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.3" upper_limit="3.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.3" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo one tablet daily for 12 months</description>
        </group>
        <group group_id="E2">
          <title>Eplerenone</title>
          <description>eplerenone one tablet daily for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>death due to fat embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache coincident with seasonal allergies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Subha V. Raman, MD</name_or_title>
      <organization>The Ohio State University</organization>
      <phone>(614)293-8963</phone>
      <email>raman.1@osu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

